MD Perspective : Onchomycosis ( nail bed fungal infection) is a VERY common, difficult to treat condition . Essentially, current topical medications are marginally effective. Nail removal not an alternative easy to contemplate, and again in some patients ineffective. The current systemic medication poses a definite serious health risk in some patients ie- Liver failure and a serious Immune type ailment. If Anacor's current phase three clinical investigation proves successful , their medication will be accepted as the standard of care for most Dermatologists and Podiatrists , as well as other MDs. The firms other drug candidates also seem attractive treatments for atopic dermatitis and psoriasis , again, two common conditions where newer alternatives to current therapy needed.
I agree that the market is potentially a good one and will make money for investors but the company must be sure to court the payers as there will be resistance because of cost. I have a significant holding of the stock.